<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222843</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-III-ITP</org_study_id>
    <nct_id>NCT03222843</nct_id>
  </id_info>
  <brief_title>Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient</brief_title>
  <official_title>A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with&#xD;
      chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain&#xD;
      platelet counts 50~250×109/L&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients with a platelet count ≥50×109/L after Day 57.</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral hetrombopag at an initial dose of 2.5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral hetrombopag at an initial dose of 5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo at an initial dose of 2.5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo at an initial dose of 5 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine</intervention_name>
    <description>once daily</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of ITP ≥6 months;Platelets &lt;30×109/L.&#xD;
&#xD;
          2. No evidence of other causes of thrombocytopenia.&#xD;
&#xD;
          3. Subjects who are refractory or have relapsed after at least one prior ITP therapy.&#xD;
&#xD;
          4. Previous therapy for ITP including rescue must have been completed at least 2 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
          5. Subjects treated with maintenance immunosuppressive therapy must be receiving a dose&#xD;
             that has been stable for at least 1 month.&#xD;
&#xD;
          6. PT result no exceed normal by more than ±3s,APTT result no exceed normal by more than&#xD;
             ±10s.&#xD;
&#xD;
          7. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any prior history of arterial or venous thrombosis，or diagnosis as&#xD;
             Thrombophilia.&#xD;
&#xD;
          2. Subjects diagnosed with tumor.&#xD;
&#xD;
          3. Have pre-existing cardiac disease within the last 3 months.No arrhythmia known to&#xD;
             increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a&#xD;
             Corrected QT interval (QTc) &gt;450msec or QTc &gt;480 for patients with a Bundle Branch&#xD;
             Block.&#xD;
&#xD;
          4. Female subjects who are nursing or pregnant at screening or pre-dose on baseline.&#xD;
&#xD;
          5. Subjects who have previously received eltrombopag or any other thrombopoietin receptor&#xD;
             agonist within 30 days .&#xD;
&#xD;
          6. Subject has consumed aspirin, aspirin-containing compounds, salicylates,&#xD;
             anticoagulants, quinine or non-steroidal anti-inflammatories (NSAIDs) for &gt;3&#xD;
             consecutive days within 2 weeks of the study start and until the end of the study.&#xD;
&#xD;
          7. Any laboratory or clinical evidence for HIV infection.Any clinical history for&#xD;
             hepatitis C infection; chronic hepatitis B infection; or any evidence for active&#xD;
             hepatitis at the time of subject screening.&#xD;
&#xD;
          8. ALT&gt; 1.5 x upper limit of normal (ULN), AST&gt; 3 x upper limit of normal (ULN)) DBLI&gt;&#xD;
             1.2 x upper limit of normal (ULN),Scr&gt; 1.2 x upper limit of normal (ULN)&#xD;
&#xD;
          9. The subject has participated in other clinical trial within the 3 months prior to&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Hu, Ph.D</last_name>
      <email>dr_huyu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Heng Mei, Ph.D</last_name>
      <email>mayheng@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ting Niu, MD</last_name>
      <email>tingniu@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Blood Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renchi Yang, MD</last_name>
      <email>rcyang65@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

